DocWire News Editors

DocwireNews

Following radical prostatectomy, radiotherapy is the standard salvage treatment. Researchers assessed the impact of adding short-term hormonotherapy to radiotherapy and found that this significantly improved 10-year metastatic-free survival (MFS). The results of the randomized, open-label, phase III study were presented at the 2019 ASCO Annual Meeting.
A total of 743 patients were randomized 1:1 to receive radiotherapy (66 Gy/46 Gy) alone or in combination with goserelin for six months. Patients were stratified based on radiotherapy modality and risk group. Low-risk disease was defined as a Gleason score less than eight, surgical margins prostate-specific antigen doubling time greater than eight months, and no seminal vesicle involvement. Biological relapse was defined according to the American Society for Radiation Oncology consensus.
At data cutoff (March 2019), the median duration of follow-up was 112 months. The researchers observed a benefit in progression-free survival (PFS; primary outcome) in the radiotherapy plus hormonotherapy cohort (hazard ratio [HR] = 0.54; 95% confidence interval [CI], 0.43-0.68; P&lt;0.0001). This benefit was observed in both low- (HR=0.47; 95% CI, 0.28-0.80) and high-risk (HR=0.56; 95% CI, 0.44-0.73) cohorts.
MFS was significantly improved in the radiotherapy plus hormonotherapy cohort (75%; 95% CI, 70-80) compared with the radiotherapy alone group (69%; 95% CI, 63-74) at 10 years (HR=0.73; 95% CI, 0.54-0.98; P=0.034).
In a 2016 study published in The Lancet Oncology, the researchers conducted a similar study in which patients received standard salvage radiotherapy or radiotherapy plus short-term goserelin. After a median follow-up of 5.3 years, the researchers observed a benefit in PFS in the combination cohort (80% vs. 62%; P&lt;0.0001), regardless of patient risk status.
“Considered in the context of previously published results, [this recent study confirms] that this strategy can be considered as the new standard for salvage treatment after radical prostatectomy,” the researchers concluded.
Reference
Carrie C, Magné N, Burban-Provost P, et al. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475). Abstract #5001. Presented at the 2019 ASCO Annual Meeting, Chicago, IL, May 31, 2019.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

A New Standard of Care? Addition of Hormonotherapy to Radiotherapy Improves Survival in Prostate Cancer

ASCO 2019

Following radical prostatectomy, radiotherapy is the standard salvage treatment. Researchers assessed the impact of adding short-term hormonotherapy to radiotherapy and found ...

A New Standard of Care? Addition of Hormonotherapy to Radiotherapy Improves Survival in Prostate

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe